New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients with blood cancer who have tried all other therapeutic options and continue to relapse. Specifically, this treatment is being used for some types of acute myeloid leukemia (AML) as well as myelodysplastic syndromes (MDS), which are both rare blood cancers. 40% of patients who have received traditional therapies relapse and a relapse is the leading cause of death for these conditions.
The safety and the efficacy of this therapy is still in the process of investigation. Dr. Juan Carlos Varela is the principal investigator of this therapy.

How it Works

This therapy is personalized and customizable for the patient. It takes a few simple steps. First, white blood cells are removed from a donor. This donor must have previously donated their stem cells to the blood cancer patient. Next, tumor-specific immune cells are generated. Finally, these new cells are administered back to the patient through their blood stream. These new cells attack the cancerous cells in the body.

The very first patient to be given this therapy received it in April. They are now recovering in their home. Doctors are monitoring him to determine the efficacy of the treatment. They believe this observation stage may take months.

Considering how limited the treatment options for AML and MDS currently are, there is an urgent need for more research. This therapy could be life-saving for patients but more investigation is still needed.

This company believes that personalized therapies are the future of healthcare for cancer patients. Antigen-Specific T-Cell Therapy is just one of the moves in this direction.  

You can read more about this investigative therapy here.

Share this post

Follow us